Wegovy vs Zepbound: Comparing the Two Weight-Management Shots
Two different once-weekly medicines approved for the same goal, one head-to-head trial to reason from, and one app that tracks whichever your prescriber picks.
Quick verdict
Wegovy (semaglutide) and Zepbound (tirzepatide) are different weight-management medicines. In SURMOUNT-5, the one head-to-head trial, tirzepatide averaged about 20.2% weight loss versus 13.7% for semaglutide at 72 weeks, but an average points a direction, not a personal promise. MeAgain tracks whichever one your prescriber picks.
Wegovy works on one appetite pathway and Zepbound on two, so there is no single answer that fits everyone. Unlike most GLP-1 pairs, these two were tested head-to-head: in the SURMOUNT-5 trial, tirzepatide at 10 or 15 mg reached about 20.2% average weight loss and semaglutide at 1.7 or 2.4 mg about 13.7% at 72 weeks. That is a genuine head-to-head result, but averages hide a wide range, so it points a direction rather than promising an outcome for any one person. They also differ in how long they stay in the body: semaglutide has about a 1-week half-life, tirzepatide about 5 to 6 days. MeAgain does not pick one for you. It is the daily app layer once the prescription starts, and 500K people track their GLP-1 with it, rated 4.8 stars across 23K App Store ratings.
Bottom line: This page is education, not medical advice. Medication choice and dose changes belong with your doctor or licensed clinician. MeAgain works with any GLP-1, branded or compounded, wherever it is prescribed.
Key takeaways
Wegovy and Zepbound are different medicines, both approved for weight management. Wegovy is semaglutide and Zepbound is tirzepatide, so this is a real drug-to-drug comparison, not two versions of one drug.
Wegovy works on one appetite pathway and Zepbound on two. Both are once-weekly injections, and MeAgain's medication graph fits either weekly rhythm so you can see where a dose is rising, peaking, and fading.
The dose ladders differ and sit on different scales. Wegovy steps 0.25, 0.5, 1, 1.7, 2.4 mg (with a 7.2 mg Wegovy HD maximum for some adults), and Zepbound steps 2.5, 5, 7.5, 10, 12.5, 15 mg. MeAgain keeps your current step and next-dose countdown in one view.
In SURMOUNT-5, a head-to-head trial, tirzepatide (10 or 15 mg) reached about 20.2% average weight loss and semaglutide (1.7 or 2.4 mg) about 13.7% at 72 weeks. That is a real head-to-head result, but averages hide a wide range, so it shows direction, not a promise for any one person.
If your prescriber switches you between them, MeAgain keeps your weight trend, food logs, side effects, and dose dates on one timeline so nothing resets and you can compare how your own body responded before and after.
What MeAgain Does After You and Your Prescriber Choose
01One graph, two weekly rhythms
Wegovy and Zepbound move through the week differently, and MeAgain's medication graph adjusts to the semaglutide or tirzepatide rhythm. Semaglutide lingers for about a week, while tirzepatide tapers a little faster at about five to six days, so the curve is not identical. On the graph you can watch a dose climb, hold, and ease off, and see medication levels as the week progresses instead of guessing why one day feels different from the next. Appetite and side effects often track that curve, so having it in front of you makes a dose increase easier to read against how you actually felt. You do not build it by hand: set the medicine and dose, and the weekly shape is drawn for you, then redrawn if your prescriber changes the plan.
02Your current step and next-dose countdown
The two dose ladders are different lengths and sit on completely different scales, so MeAgain tracks each on its own terms rather than lining the numbers up against each other. Your current step stays visible, the countdown to your next shot is always one glance away, and every dose you log records the injection site so the app rotates you to a fresh spot next time. When your prescriber steps you up the ladder, you move the setting and nothing else resets. That matters most in the weeks when you are deciding whether to hold at your current dose or step up, because a clean record of what you have taken and how you felt is exactly what you want to bring to that conversation.
03Side effects and food, logged the same way
A trial average cannot tell you how you will feel, so your own log matters more than a chart. MeAgain tracks the 18 most common GLP-1 side effects plus unlimited custom symptoms on a simple 0 to 10 scale, then lets you read those entries next to protein, water, fiber, meals, and your weight trend. Over a few weeks the pattern gets easy to see: maybe nausea settled after the first couple of days on a new step, or maybe appetite came back before the next shot was due. Five ways to log food keep nutrition fast enough to use on ordinary days, not just perfect ones. Whether your prescriber picks Wegovy or Zepbound, the logging works the same way, so your routine does not change if the medicine does.
04Switch without starting over
Plenty of people do not stay on the first medicine forever. Insurance changes, side effects shift, supply comes and goes, and a prescriber may move you from one to the other. In MeAgain a switch is a settings change, not a fresh start: your weight trend, food logs, symptom history, and every past dose stay on one timeline, and the medication graph swaps from the semaglutide rhythm to the tirzepatide one, or back. You do not open a new spreadsheet or lose the context from your first months. The most useful comparison of Wegovy and Zepbound is rarely the trial chart. It is what your own body did in the weeks before and after a change, and that only exists if the whole history lives in one place.
Wegovy vs Zepbound: What Actually Changes
What the Head-to-Head Trial Does and Does Not Tell You
In SURMOUNT-5, a head-to-head trial that put the two medicines side by side, people on tirzepatide (10 or 15 mg) lost about 20.2% of their weight on average and people on semaglutide (1.7 or 2.4 mg) about 13.7% at 72 weeks. That is a genuine head-to-head result, not two separate studies compared after the fact, and it points to tirzepatide leading on average. That distinction matters, because most GLP-1 comparisons rely on separate trials with different participants, while this one measured both drugs in the same study.
The catch is that an average is not a promise. Some people lose more, some less, and side effects, consistency, needle comfort, insurance, and your own health history all weigh in as much as the molecule. The two medicines also differ in how long they stay in the body, with semaglutide lasting about a week and tirzepatide about five to six days, so the weekly fade looks a little different on the graph. The most useful comparison is not the trial chart. It is what happens in your own body over the weeks that follow, which is exactly what a daily log lets you see.
Wegovy vs Zepbound at a Glance
| Question | Wegovy | Zepbound |
|---|---|---|
| Medicine | Semaglutide | Tirzepatide |
| How it works | One appetite pathway (GLP-1) | Two appetite pathways (GIP and GLP-1) |
| Approved for | Weight management | Weight management (and obstructive sleep apnea) |
| Dose ladder | 0.25 → 0.5 → 1 → 1.7 → 2.4 mg | 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg |
| Top dose | 2.4 mg weekly; up to 7.2 mg (Wegovy HD) for some adults | 15 mg weekly |
| Half-life | About 1 week | About 5 to 6 days |
| Head-to-head result (SURMOUNT-5) | About 13.7% average loss at 72 weeks (on 1.7 or 2.4 mg) | About 20.2% average loss at 72 weeks (on 10 or 15 mg) |
| Maker | Novo Nordisk | Eli Lilly |
These are label and trial facts, not a ranking. The two weight-loss numbers come from SURMOUNT-5, a head-to-head trial; they are averages, and individual results vary widely. The trial tested semaglutide at 1.7 or 2.4 mg and tirzepatide at 10 or 15 mg, so its result predates the newer 7.2 mg Wegovy HD dose. The milligram numbers are on different scales and should not be compared directly.
How to Think About the Choice
- Both are approved for weight management, so this is a real drug-to-drug comparison, and SURMOUNT-5 is the one head-to-head trial to reason from.
- On average, tirzepatide (Zepbound) led semaglutide (Wegovy) in SURMOUNT-5, but an average points a direction, it does not promise an outcome for any one person.
- Do not read the dose ladders across each other. The numbers sit on different scales, and your prescriber sets the step, not a comparison chart.
- Side effects, consistency, needle comfort, insurance, and your health history all weigh in beyond the trial number, so the honest choice is personal.
- If you might switch later, keep the whole timeline intact so you can compare your own before-and-after, which beats any trial average.
The tracker works whether you stay on Wegovy, move to Zepbound, or change again later. Your weight trend, meals, symptoms, and dose history stay on one timeline through every switch, and MeAgain works with any GLP-1, branded or compounded, wherever it is prescribed.
This content is for informational purposes only and does not constitute medical advice. Drug choice, dose changes, and side-effect management should be decided with your doctor or licensed clinician. Brand-name products referenced here are made by Novo Nordisk or Eli Lilly.
The Comparison Starts With the Drug. The Daily Work Starts After.
One App Across Both Medicines
Two numbers from a trial cannot tell you which medicine will fit your life. The weekly rhythm, the side effects, the meals, and the weight trend over months tell that story, and they are easier to read when they all live in one place. That daily view is what reviewers tend to describe once the medicine settles into a routine.
Down 23.8 pounds! Minimal side effects. I appreciate the app showing me medication levels as the week progresses as well as the encouragement.
That is the pattern on either shot. The medicine may change from Wegovy to Zepbound, but the shot day, the symptoms, and the weight trend you track carry straight across.
MeAgain was built for the whole GLP-1 category, not one brand: a weekly medication graph, a next-dose countdown, injection-site rotation, side-effect logging on a 0 to 10 slider, five ways to log food, and a weight trend that stays one continuous line. Whether your prescriber picks Wegovy or Zepbound, branded or compounded, the app fits and your history does not start over.
What Our Users Say
“I've been using the app for about 7 months now and I love how I'm able to track my meals and my daily medication. The little capybara widget is a great visual to help me know what my body needs.”
“This app does exactly what I needed with tracking shots… location, time, amount, current medication level, and reminders for the next one. That plus weight progress is all I needed, and after trying at least 5 others this was the only one that did it in a clean, logical way- and didn't cost a fortune!”
“I really love this app and how easy it is to use for my food, water, Mounjaro weekly shot and everything else. The app is totally worth the cost and it's been perfect for me.”
“I've been on my MJ journey since September 2025. Seeing my food intake has made a huge difference. Also, reviewing my shot locations has helped me remember to rotate. I have recommended this app to my friends who have also started their own journeys!”
“I love tracking water, protein and fiber on the app. It's really cool it's able to pull my weight and steps too. Add the widget to you phone screen if you do get it, I love that.”
Wegovy vs Zepbound FAQs
They are different medicines, both approved for weight management. Wegovy is semaglutide, which works on one appetite pathway, and Zepbound is tirzepatide, which works on two. They have different dose ladders and stay in the body for different lengths of time, with semaglutide lasting about a week and tirzepatide about five to six days. Unusually for a GLP-1 pair, they were tested head-to-head in the SURMOUNT-5 trial, where tirzepatide led on average, though averages hide a wide personal range. Both are once-weekly injections, and your prescriber decides which fits your goal and health history. MeAgain tracks either one so your shot day, symptoms, meals, and weight trend stay in a single place.
Your Journey Back to You,
One Day at a Time
Track the plan, dose, meals, and milestones in one place that actually keeps up with your day.